Melanocortins
-
CLINUVEL Advances Novel Pharmaceutical Formulations in Preclinical Program
CLINUVEL (NASDAQ:CLVLY) announced advancements in novel sustained-release liquid drug formulations after 10 years of research. The company is proceeding to preclinical evaluation of drug release profiles, aiming to extend peptide drug release, especially melanocortins, using biocompatible systems for flexible dosing. This technology may benefit diverse patient groups. The preclinical program’s completion is expected in H2 2026. The new depot formulations would serve as a platform for the delivery of various peptides, with an initial focus on melanocortins.
